

1 **TITLE**

2 **Accumulation of dihydrosphingolipids and neutral lipids is related to**
3 **steatosis and fibrosis damage in human and animal models of non-**
4 **alcoholic fatty liver disease**

5

6 **RUNNING TITLE**

7 **Dihydrospingolipids are accumulated in NAFLD**

8

9 **AUTHORS**

10 Bohdan Babiy (1), Bruno Ramos-Molina (2), Luis Ocaña (5), Silvia Sacristán (3), Diego Burgos-
11 Santamaría (4), Javier Martínez-Botas (3,6), Gemma Villa-Turégano (3), Rebeca Busto (3,6), Cristian
12 Perna (7), M. Dolores Frutos (8), Agustín Albillos (4,9), Óscar Pastor (1,6)*.

13

14 **AFFILIATIONS**

15

16 (1) Servicio de Bioquímica Clínica, UCA-CCM, HU Ramón y Cajal-IRYCIS, Madrid, Spain.

17 (2) Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain.

18 (3) Servicio de Bioquímica-Investigación, HU Ramón y Cajal-IRYCIS, Madrid, Spain.

19 (4) Servicio de Gastroenterología, HU Ramón y Cajal-IRYCIS, Madrid, Spain.

20 (5) Servicio de Cirugía General. HCU Virgen de la Victoria. Málaga, Spain.

21 (6) CIBER de Fisiología de la Obesidad y Nutrición (CIBEROBN), ISCIII, Spain.

22 (7) Servicio de Anatomía Patológica. HU Ramón y Cajal-IRYCIS, Madrid, Spain.

23 (8) Departamento de Cirugía General y Aparato Digestivo, HU Virgen de la Arrixaca, Murcia,
24 Spain.

25 (9) CIBER de Enfermedades Hepáticas y Digestivas (CIBEREHD), ISCIII, Spain.

26

27 **Corresponding author**

28 Óscar Pastor Rojo,

29 Servicio de Bioquímica Clínica, Hospital Universitario Ramón y Cajal, Ctra. de Colmenar km 9, E-
30 28034, Madrid, Spain.

31 Phone/fax: 00(34)913368950 / 00(34)913368058.

32 email: oscar.pastor@salud.madrid.org

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 ORCID ID: <https://orcid.org/0000-0002-4368-433X>

34 **Key words**

35 NAFLD, MAFLD, NASH, lipidomics, sphingolipids, ceramides, dihydroceramides.

36 **Financial support**

37 This work was supported by grants from the Instituto de Salud Carlos III, Spain (PI18/01152,
38 PI21/01173 & and PI20/00505), the Ministerio de Ciencia e Innovación, Spain (RTI2018-098113-
39 B-I00, Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020) and CIBER
40 de Fisiopatología de la Obesidad y Nutrición, CIBEROBN, (OBN-18PI032018); all the grants co-
41 financed by the European Development Regional Fund (ERDF, "*A way to make Europe*"). CIBER
42 de Fisiopatología de la Obesidad y Nutrición is an initiative of ISCIII. B.B. is supported by pre-
43 doctoral contracts (PEJD-2017-PRE/BMD-4142 and PEJD-2019-PRE/BMD-15962) of the
44 Comunidad Autónoma de Madrid (CAM). R.B. and J.M-B. is a researcher from FIBio-HRC
45 supported by Consejería de Sanidad (CAM). BR-M was supported by the "Miguel Servet Type I"
46 program (CP19/00098, ISCIII, Spain; co-funded by the Fondo Europeo de Desarrollo Regional-
47 FEDER).

48 **Author's contribution**

49 Babiyy B. (BB), Pastor O. (PO), Sacristán S. (SS), and Busto R. (BR), experiments on animals.
50 Ramos-Molina, B (RMB), María Dolores Frutos (MDF), Ocaña L. (OL), Burgos-Santamaría D.
51 (BD) and Albillos A. (AA), recruitment of patients. Perna C. (PC) and SS histology and
52 immunohistochemistry. PC and PO scoring of patient and mouse liver biopsies. BB, PO and Villa-
53 Turégano G (VTG), lipidomics, biochemistry assays, protein expression. Botas-Martínez J. (BMJ)
54 gene expression. PO conceived the study. PO, RMB, LO, AA designed and supervised the study.
55 PO & BB analysed, curated the data and generated the figures. PO wrote the manuscript. All
56 authors read the manuscript and provided feedback.

57 **Conflicts of interest**

58 The authors declare that they have no conflicts of interest with the contents of this article.

59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85

Abbreviations

A—Activity; **α-SMA**—Aortic smooth muscle actin (also named ACTA2); **ACer**— 1-o-Acylceramides ; **AUC**—Area under the curves; **BMI**—Body mass index; **BW**—Body weight; **CCl₄**—Carbon tetrachloride; **CE**—Cholesteryl esters; **Cer**—Ceramide; **Cers**—Ceramide synthase; **CK18**—Apoptosis-associated caspase-cleaved keratin-18; **COL1A1**—Collagen alpha-1(I) chain ; **dhCer**—Dihydroceramides; **dhHexCer**—Dihydrohexosylceramide; **dhSM**—Dihydrosphingomyelin; **ELF**—Enhanced liver fibrosis score; **F**—Fibrosis; **FA**—Fatty acid; **FFA**—Free fatty acids; **FIB-4**—Fibrosis-4 index; **HA**—Hyaluronic acid; **hCLS**—Hepatic crown-like structures; **HDLc**—HDL cholesterol ; **HexCer**—Hexosylceramide; **HFD**—High-fat diet; **HOMA-IR**—Homeostatic model assessment for insulin resistance; **HSCs**—Hepatic stellate cells ; **HSP90**—Heat shock protein 90; **LW**—Liver weight; **MAFLD**—Metabolic associated fatty liver disease; **NAFL**—Non-alcoholic fatty liver; **NAFLD**—Non-alcoholic fatty liver disease; **NASH**—Non-alcoholic steatohepatitis; **NASHF**—NASH-fibrosis; **NFS**—NAFLD fibrosis score; **OGTT**—Oral glucose tolerance test; **PLIN2**—Perilipin-2; **PNIIP**—Procollagen III aminoterminal peptide; **S**—Steatosis; **SM**—Sphingomyelin; **SREBP1c**—Sterol regulatory element binding factor-1c; **T2DM**—Type II diabetes mellitus; **TG**—Triglycerides; **TIMP1**—Tissue inhibitor of metalloproteinase-1; **VLCFA**—Very-long chain fatty acids.

Word Count: 5883 (abstract and references not included)

Figures: 6

Tables: 2

86 **LAY SUMMARY (63 words)**

87 Accumulation of triglyceride and cholesteryl ester lipids is the hallmark of non-alcoholic fatty
88 liver disease. Using lipidomics, we examined the role of significantly less abundant but potentially
89 harmful dihydrosphingolipids in NAFLD progression. Our results demonstrate that *de novo*
90 dihydrosphingolipid synthesis is an early event in NAFLD and the concentrations of these lipids are
91 correlated with histological severity in both mouse and human disease.

92

93 **HIGHLIGHTS (58 words)**

- 94 • Neutral lipids and dihydrosphingolipids accumulate in liver in correlation with the histological
95 severity of NAFLD in both mice and humans.
- 96 • The ceramide pathway is stimulated to alleviate the free fatty acid excess in liver of NAFLD
97 models.
- 98 • Appearance of significant fibrosis is associated with reduced concentrations of neutral lipids but
99 not dihydrosphingolipids in a mouse model of NAFLD.

100

101

102

103

104 **ABSTRACT (280 words)**

105 Background: Dihydroshingolipids are lipid molecules biosynthetically related to ceramides.
106 An increase in ceramides is associated with enhanced fat storage in the liver and inhibition of their
107 synthesis is reported to prevent the appearance of steatosis in animal models. However, the precise
108 association of dihydroshingolipids with non-alcoholic fatty liver disease (NAFLD) is yet to be
109 established. We employed a diet-induced NAFLD mouse model to study the association between
110 this class of compounds and disease progression.

111 Methods: Mice were fed a high-fat diet enriched in cholesterol and supplemented with
112 glucose and fructose up to 40 weeks. A mouse subgroup was treated with carbon tetrachloride to
113 accelerate fibrosis development. Animals were sacrificed at different time-points to reproduce the
114 full spectrum of histological damage found in human disease, including steatosis (NAFL) and
115 steatohepatitis (NASH) with and without significant fibrosis. Blood and liver tissue samples were
116 obtained from patients (n=195) whose NAFLD severity was assessed histologically. Lipidomic
117 analysis was performed using liquid chromatography-tandem mass spectrometry.

118 Results: Triglyceride, cholesterol ester and dihydroshingolipid levels were increased in the
119 liver of model mice in association with the degree of steatosis. Dihydroceramide concentrations
120 increased with the histological severity of the disease in liver samples of mice (0.024 ± 0.003 vs
121 0.049 ± 0.005 , non-NAFLD vs NASH-fibrosis, $p < 0.0001$) and patients (0.105 ± 0.011 vs $0.165 \pm$
122 0.021 , $p = 0.0221$). Several dihydroceramide and dihydroshingomyelin species were increased in
123 plasma of NAFLD patients and correlated with accumulation of liver triglycerides.

124 Conclusions: Dihydroshingolipids accumulate in the liver in response to increased free fatty
125 acid overload and are correlated with progressive histological damage in NAFLD. The increase in
126 dihydroshingolipids is related to upregulation of hepatic expression of enzymes involved in *de*
127 *novo* synthesis of ceramides.

128 INTRODUCTION

129 Non-alcoholic fatty liver disease NAFLD (also recently designated 'metabolic associated fatty
130 liver disease', MAFLD) (1) is a growing health issue related to the epidemic of obesity and diabetes
131 in developed countries. The incidence of cirrhosis associated with NAFLD has increased
132 significantly over the years and is considered one of the main causes of chronic liver disease
133 worldwide (2). However, the key drivers leading to predisposition to the development of
134 steatohepatitis (NASH) and fibrosis, the main factors associated with poor outcomes, are currently
135 unknown (3, 4). The lipotoxicity hypothesis proposes that in the early phases of NAFLD (simple
136 steatosis or NAFL), neutral lipids, such as triglycerides (TG) and cholesterol esters (CE),
137 accumulate in the liver in response to the influx of free fatty acids (FFA) from adipose tissue, which
138 corresponds with the appearance of peripheral and hepatic insulin resistance (5). Moreover, FFAs
139 trigger the synthesis of the less abundant but potentially harmful ceramides (Cer), dihydroceramides
140 (dhCer), and other biosynthetically related sphingolipids and dihydrosphingolipids (**Suppl Fig. 1**).
141 The majority of evidence on the involvement of sphingolipids and dihydrosphingolipids
142 (collectively termed (dihydro)sphingolipids) in NAFLD has been obtained from knockout studies
143 on animals (reviewed in (6, 7)). Earlier studies clearly demonstrate that increase in liver Cer is
144 associated with enhanced FFA uptake, TG storage and impaired glucose utilization in the liver,
145 none of which could be replicated with dhCer (8). Hence, strategies to prevent the increase in liver
146 Cer using inhibitors of serine palmitoyltransferase (*Sptlc*) such as myriocin (9) or blocking the
147 conversion of dhCer to Cer with dihydroceramide desaturase inhibitor (*Degs1*) have been effective
148 in avoiding early steatosis in animal models (10, 11).

149 Limited studies to date have examined the relationship between (dihydro)sphingolipid
150 accumulation in diet-induced mouse models of NAFLD. Kim et al. (10) reported an increase in the
151 concentration of Cer 34:1 (C16-Cer) in response to a high-fat diet (HFD) enriched in palmitic acid
152 (FA 16:0) at 24 weeks, coincident with increased expression of ceramide synthase (*Cers6*) and
153 associated with higher lipogenesis rates mediated by the nuclear factor SREBP1c (10). In keeping

154 with this finding, the increase in C16-Cer promoted steatosis in the liver, whereas ceramides
155 containing very-long-chain fatty acids (VLCFA) synthesized by *Cers2* isoenzymes (such as Cer
156 40:1 and Cer 42:1) protected against early NAFL (12). Short-term administration of carbon
157 tetrachloride (CCl₄), a toxic agent inducing fibrosis progression in mice fed a normal diet, is
158 reported to enhance liver Cer (13). However, studies focusing on the association of
159 (dihydro)sphingolipids with disease progression to NASH and significant stages of fibrosis (NASH-
160 fibrosis) in animal models are lacking.

161 Similarly, incomplete results on the relationship between (dihydro)sphingolipids and NAFLD
162 progression have been obtained in human studies. A number of earlier investigations reported
163 increased Cer levels in plasma and liver NAFL and NASH patients (14, 15), while recently
164 publications specifically document an increase in dihydrosphingolipids, – dihydroceramide (dhCer)
165 and dihydrosphingomyelin (dhSM) – in plasma (16, 17) and liver (18, 19). The reliability of
166 conclusions from studies on the involvement of (dihydro)sphingolipids in NAFLD is hampered by
167 the lack of histological representation of the full spectrum of the disease and limited coverage of the
168 dihydrosphingolipid species.

169 Cross-examination of the roles of sphingolipids and dihydrosphingolipids in relation to the
170 histological course of disease is necessary to understand the involvement of this class of lipids in
171 pathogenesis, which may be of relevance in establishing optimal candidate molecular targets of the
172 ceramide pathway to inhibit progression. The main aim of the current study was to determine the
173 potential associations of (dihydro)sphingolipid changes with histological grading and staging in
174 NAFLD. To address this issue, we compared findings from a diet-induced mouse model of NAFLD
175 and human patients. Our collective results showed that dihydrosphingolipids are more closely
176 related with histological damage than sphingolipids, especially steatosis and therefore neutral lipid
177 accumulation, in both mice and humans.

178

179 **METHODS**

180 A full description of the methods is provided in the **Supplementary Methods section**.

181 *Animal housing conditions*

182 Mice were housed in the animal facility of Hospital Universitario Ramón y Cajal (Num. Reg:
183 ES 280790000092) in a temperature-controlled room under a 12 light/dark cycle with *ad libitum*
184 access to food and water. All interventions were performed during the light cycle in accordance
185 with legislation in Spain (RD 53/2013) and the European Directive (2010/63/EU) and approved by
186 the Ethics Committee of the Ramón y Cajal Hospital, Madrid (ES-280790002001).

187 *Diets and treatments*

188 Six week-old C57BL/6J male mice received either standard rodent chow or a high-fat diet
189 (HFD) enriched with cholesterol (1.25%) and a high sugar solution of fructose and glucose in
190 drinking water up to 40 weeks. At 22 weeks, a subset of animals received a weekly intraperitoneal
191 injection of CCl₄ at a final dose of 0.2 μ L CCl₄/gr of body weight for 6 and 10 weeks. Animals
192 were sacrificed at predetermined time-points (**Suppl. Fig. 2**). Food was removed 6 h before death.
193 Mice were anesthetized with sevoflurane (2% in oxygen flux at 1 L/min). Blood was drawn by
194 cardiac puncture, the liver extracted, and plasma obtained after centrifugation (1900 g) for
195 biochemistry assays. The median hepatic lobe was preserved in 10% buffered formalin for
196 histological and immunohistochemical analyses.

197 *Patients*

198 We prospectively enrolled consecutive patients with obesity undergoing bariatric surgery at
199 the two hospital centers (Hospital Clínico Universitario Virgen de la Victoria de Málaga and
200 Hospital Universitario Virgen de la Arrixaca de Murcia, Spain). Inclusion criteria were age range of
201 18–65 years and obesity of more than 5 years of duration with a body mass index (BMI) ≥ 40 kg/m².

202 Additional patients in the plasma lipidomic cohort were recruited from the Gastroenterology
203 Department of Hospital Ramón y Cajal for confirmatory NAFLD diagnosis, suspected based on the
204 presence of steatosis upon abdominal ultrasound examination and/or unexplained aspartate
205 aminotransferase (AST), alanine aminotransferase (ALT) or gamma-glutamyltransferases (GGT)
206 elevation accompanied by type II diabetes mellitus (T2DM), obesity (BMI) ≥ 35 kg/m² and
207 metabolic syndrome.

208 Exclusion criteria were set based on evidence of other causes of liver disease, including viral
209 hepatitis, medication-related disorders, autoimmune disease, hepatocellular carcinoma,
210 haemochromatosis, Wilson's disease, familial/genetic causes or a previous history of excessive
211 alcohol use (>30 g daily for men and >20 g daily for women) or treatment with any drugs
212 potentially causing steatosis, such as tamoxifen, amiodarone, and valproic acid (20). The study was
213 performed in agreement with the Declaration of Helsinki according to local and national laws and
214 approved by the Ethics and Clinical Research Committees of every center: "Predictive factors of
215 histological lesions in patients with non-alcoholic fatty liver disease" (Hospital Universitario
216 Ramón y Cajal, ref: EC 276-14), "Gut microbiota and related metabolites as potential biomarkers of
217 resolution of non-alcoholic steatohepatitis and improvement of liver fibrosis after bariatric surgery"
218 (Hospital Clínico Universitario Virgen de la Araixaca, ref: 2020-2-4-HCUVA) and "Metabolomic
219 study in obese NAFLD/NASH patients subjected to bariatric surgery" (Hospital Clínico
220 Universitario Virgen de la Victoria de Málaga, ref: S2200002).

221 *Histology of patient liver biopsies*

222 Intraoperative wedge liver biopsies from bariatric surgery patients at least 1 cm in depth were
223 obtained. One section was snap-frozen and stored at -80°C for lipidomic analysis and the other was
224 formalin-fixed and paraffin-embedded for histological assessment. Percutaneous or transjugular
225 liver biopsy specimens (1 mm in diameter and 1.5 mm in length) were obtained from patients
226 subjected to non-bariatric surgery included in the plasma lipidomic cohort. The minimal set of

227 staining procedures included hematoxylin and eosin (H&E), Masson trichrome, Periodic acid–
228 Schiff (PAS), Perls and reticulin staining. All biopsies were reviewed and scored by trained liver
229 pathologists from the recruitment centers (**Supplementary methods**).

230 *Histology of mouse liver biopsies*

231 Mouse liver tissue sections were stained with H&E and picosirius red and evaluated in a
232 blinded manner by an experienced pathologist (P.C). Histological scoring in mice was performed
233 using the SAF (Steatosis, Activity and Fibrosis) classification system proposed by Bedossa (21)
234 (**Supplementary methods**).

235 *Western blot*

236 Homogenized liver tissue extracts were diluted to 1 mg/mL in lysis buffer (described in
237 **Supplementary methods**) and protein concentrations in the extracts assessed using the
238 bicinchoninic acid assay. For measurement of expression, 40 µg protein was loaded onto 10% SDS
239 gels for electrophoresis and transferred to nitrocellulose membranes. After blocking (0.1% solution
240 of casein in TBS w/v), blots were incubated with primary antibodies for actin alpha 2/ α -smooth
241 muscle actin (ACTA2/ α -SMA; dil 1:1000 v/v), perilipin 2 (PLIN2; dil 1:4000 v/v), sequestosome 1
242 (p62; dil 1:4000 v/v), collagen type I Alpha 1 chain (Col1A1; dil 1:2000 v/v) and heat shock protein
243 90 (HSP90; dil 1:2000 v/v), followed by secondary antibodies conjugated to IRDye 800 CW or
244 IRDye 680 LT (LI-COR, Lincoln, NE, USA). Quantification of bands was performed via
245 densitometry using the Odyssey Infrared Imaging System V.3.0 and normalized to the intensity of
246 the loading control (HSP90).

247 *Real-time PCR gene expression*

248 Homogenized liver tissue was extracted using an RNeasy-Plus Universal Mini Kit and the
249 QIAcube automated purification system (Qiagen, Maryland-USA) according to the manufacturer's
250 instructions. Following validation, RNA (500 ng) was reverse-transcribed with random hexamers

251 using the PrimeScript RT reagent kit (Takara, California-USA). Real-time PCR amplification was
252 performed on a LightCycler 480 II using the SYBR Green I Master kit (Roche, Basel-Switzerland)
253 on 384-well plates. Data were analyzed using the relative quantification method described by Pfaffl
254 (22), based on the mean values of three housekeeping genes (*18S ribosomal RNA [Rn18s]*,
255 *cyclophilin B [Cypb]*, and *Human ribosomal protein large P0 [Rplp0]*) as invariant endogenous
256 controls for each sample as described in **Supplementary methods**.

257 *Oral glucose tolerance test*

258 Oral glucose tolerance test (OGTT) was performed in mice after 5 h of fasting (23) . For this
259 experiment, mice were administered an oral solution of glucose (0.5 g/mL) using a gavage needle (2
260 g glucose/kg body weight). Blood glucose measurements were conducted on samples (obtained via
261 tail nicking) at 0, 15, 30, 60, and 120 min with the aid of a glucometer (Performa-Accu-Chek.
262 Roche, Basel-Switzerland).

263 *Blood biochemistry assays*

264 Glucose, AST, ALT, total cholesterol (Chol), total triacylglycerols (Trig), HDL cholesterol
265 (HDLc), insulin, and other blood clinical chemistry measurements were performed using an
266 Architect ci16000 system (Abbott Diagnostics, Illinois-USA). The glycated haemoglobin (HbA1c)
267 level was analyzed using Hb9210 Premier equipment (A. Menarini Diagnostics, Florence-Italy).
268 Free fatty acid (FFA) levels in plasma and liver tissue were measured using a specific ELISA kit
269 (Elabscience, Houston-USA). Procollagen III aminoterminal peptide (PNIIP), Hyaluronic acid
270 (HA) and metalloproteinase inhibitor 1 (TIMP1) in plasma were analyzed on an ADVIA-Centaur
271 XPT system (Siemens Healthineers, Malvern-USA) and cytokeratin 18 (CK18) evaluated using an
272 ELISA kit (PEVIVA, Stockholm-Sweden).

273 *Lipidomic analyses of plasma and liver tissue samples*

274 Lipid species were analyzed using targeted liquid chromatography coupled to tandem mass
275 spectrometry following a previously described validated workflow (24). Lipids from homogenized
276 liver tissue (equivalent to 250 µg of total protein) or plasma (50 µL) were extracted following
277 Folch's methodology (25). A mixture (10 µL) containing one internal standard per lipid class was
278 added to all samples before lipid extraction for molar quantification. Analysis of several batches
279 was necessary for processing on different days. To reduce analytical variability for every batch, we
280 analyzed a self-validated plasma calibrator and three different levels of quality controls. Using this
281 approach, the analytical within-day and between-day relative standard deviations (RSDs) were kept
282 below 20% for the 130 species of the 13 different lipid classes (**Suppl. Fig. 9**).

283 *Statistical analysis*

284 Statistical analyses were conducted using R software version 3.5.1 (<http://www.r-project.org>).
285 One-way ANOVA comparisons for quantitative variables between more than two groups were
286 conducted and in cases of significance, post-hoc paired comparisons performed using the Student's
287 t-test. Comparison between qualitative variables was performed using the Chi-square (χ^2) test. P-
288 values of less than 0.05 were considered significant. Correlations between quantitative variables
289 were examined using Pearson's correlation coefficient. Hierarchical cluster analysis was performed
290 with the aid of k-means algorithm using euclidean distances.

291 *Data availability*

292 The final datasets used for manuscript preparation are available at Zenodo repository
293 (<https://doi.org/10.5281/zenodo.6122303>).

294

295

296 **RESULTS**

297 *Metabolic characterization of the NAFLD mouse model*

298 To establish the relationship between (dihydro)sphingolipid species and NAFLD, we initially
299 examined the characteristics of a diet-induced mouse model of NAFLD (**Suppl. Fig. 2**). Mice were
300 fed a HFD enriched in cholesterol, glucose and fructose for up to 40 weeks and ultimately sacrificed
301 at different time points (22, 30 and 40 weeks) to trace disease progression from NAFL to NASH. A
302 subset of animals was treated with CCl₄, starting at 22 weeks, but kept under the same regime to
303 accelerate progression to higher stages of fibrosis (F3-F4). Animals were sacrificed at 28 weeks (6
304 injections of CCl₄) and 32 weeks (10 injections of CCl₄) for experimental purposes.

305 HFD feeding increased the weights of animals compared with control littermates (**Fig. 1A**).
306 This increase corresponded to changes in liver weight and liver to body weight ratio (LW/BW)
307 (**Fig. 1B, C**, respectively). Conversely, administration of CCl₄ induced a decrease in both weight
308 and LW/BW. Transaminase levels in plasma (AST and ALT) were higher from 22 weeks onwards,
309 with a more significant increase at 40 weeks (**Fig. 1D, E**). Administration of CCl₄ induced a
310 decrease in transaminase levels compared to the HFD-fed group at 22 weeks. Total plasma
311 cholesterol (Chol) and HDL-cholesterol (HDLc) were increased in HFD-fed animals (**Fig. 1F, H**).
312 Surprisingly, plasma triglyceride levels were decreased in the HFD group (**Fig. 1G**). Plasma basal
313 glucose concentrations (Glu) increased from 22 weeks of feeding, showing a decay at 40 weeks or
314 after CCl₄ administration (**Fig. 1I**). This behavior was compatible with development of insulin
315 resistance (IR) in HFD mice at 22 weeks and confirmed upon glucose challenge (**Fig. 1J, K**).
316 Metabolically, the mouse model showed progressive body weight gain (obesity) accompanied by
317 IR, dyslipidemia (hypercholesterolemia) and elevated levels of biomarkers of hepatocellular
318 damage. All these factors are frequently associated with human NAFLD.

319

320 *Mouse liver histology*

321 Representative images of livers, H&E - and sirius red-stained sections are presented in **Fig. 2**.
322 At 22 weeks, HFD mice showed clear signs of neutral lipid accumulation surrounding the central
323 vein (zone 3) with predominance of microvesicular steatosis, which progressed to macrosteatosis
324 from 30 weeks onwards. An increase in inflammatory activity was evident at 30 weeks, manifested
325 by the increased presence of clusters of inflammatory cells and hepatic crown-like structures
326 (hCLS) associated with greater staining of aortic smooth muscle actin (ACTA2/ α -SMA) (**Suppl.**
327 **Fig. 3**). However, ballooned hepatocytes, a hallmark of NASH in human NAFLD, were only
328 detected at 40 weeks, concordant with the steep elevation of transaminase levels in plasma (**Fig.**
329 **1D, E**), and also observed in mice treated with CCl₄. Mild signs of perisinusoidal stage F1 fibrosis
330 were evident at 30 weeks in 5 out of 7 animals, whereas at 40 weeks, all mice showed progression
331 to perisinusoidal and periportal stage F2 fibrosis. All mice treated with CCl₄ exhibited stage F \geq 2,
332 with progression to stage 3 after 10 weeks, accompanied by lower steatosis scores, severe
333 necroinflammatory damage and formation of regenerative micronodules. For each biopsy, a SAF
334 score summarizing the main histological lesions was obtained (**Suppl. Fig 4A**).

335 Western blot analysis of protein expression of perilipin-2 (PLIN2, a marker of lipid droplet
336 formation), ACTA2/ α -SMA (a marker of stellate cell activation), p62 (a marker of Mallory-Denk
337 bodies) and collagen alpha-1(I) chain (COL1A1) associated with scar tissue formation confirmed
338 our histological findings (**Fig. 2B, C**). In a similar manner, expression patterns of genes related to
339 fatty acid transport and synthesis (*Cd36*, *Scd1*), inflammation (*Tnfa*, *Mcp1*) and fibrogenesis (*Acta2*,
340 *Tgfb1*) corroborated with the changes observed in the model (**Fig. 2D**).

341 *Time-course analysis of plasma dihydro(sphingolipid) changes in NAFLD mice*

342 Metabolic and histological findings, together with protein and gene expression changes,
343 confirmed the suitability of the mouse model for investigating the relationship between
344 (dihydro)sphingolipids and progression of NAFLD. To determine the associations of these

345 compounds with NAFLD development, changes in the plasma concentrations were monitored over
346 time. Dihydrosphingolipid classes (dhCer and dhSM) were increased early in mouse plasma only
347 after 4 weeks of HFD feeding and remained higher in the HFD-fed group during the whole follow-
348 up period. However, the increase in sphingolipids was less significant and Cer and SM areas under
349 the curves (AUC) were not markedly different from those of control mice (**Fig 3A, B**). The increase
350 in dihydrosphingolipids was coincident with that of FFA in plasma and liver tissue (**Fig. 3C**).

351 *Analysis of liver dihydrosphingolipids of the NAFLD mouse model*

352 While time of diet and exposure to CCl₄ determined disease progression in our mouse model,
353 we observed substantial heterogeneity in liver histology when these factors were solely considered
354 (**Suppl. Fig. 4A**). Accordingly, mice were further categorized based on histological findings into
355 non-NAFLD (normal diet-fed), NAFL, NASH (steatohepatitis without significant fibrosis, F0-F1),
356 and NASH-fibrosis (steatohepatitis with significant fibrosis, F2-F4) groups (**Suppl. Fig. 4B**). This
357 grouping system appears the most clinically relevant for NAFLD prognosis (3, 4) and facilitates
358 comparison with human NAFLD histology.

359 As expected, lipidomic analysis of mouse livers revealed an increase in TG and CE species in
360 NAFLD mice in concordance with the steatosis score (**Fig. 4A**). Additionally, the concentration of
361 1-o-acylceramide (ACer), a lipid derived from condensation of fatty acids to one of the free
362 hydroxyl group of ceramides, was higher, although very low relative to that of TG (**Suppl. Table**
363 **S1**). The values obtained for the dihydrosphingolipid classes (dhCer, dhSM and dhHexCer) were
364 higher in NAFLD compared to non-NAFLD mice, especially those corresponding to very-long-
365 chain fatty acid species (FA 22:0, FA 24:0 and FA 24:1) (**Fig. 4B**). We did not observe a clear trend
366 of increase for Cer although the concentration was higher in the NASH group, whereas SM was
367 specifically increased in liver of the NASH-fibrosis group. Advanced fibrosis (F3-F4) was
368 associated with reduced accumulation of TG, CE and ACer but higher levels of
369 dihydrosphingolipids (**Suppl. Fig. 5**).

370 We examined the hypothesis that the increase in dihydrosphingolipids in liver may be a result
371 of changes in the expression of enzymes implicated in their synthesis. In keeping with our
372 supposition, hepatic gene expression of enzymes involved in *de novo* sphingolipid synthesis, for
373 instance, serine palmitoyl transferases (*Sptlc1* and *Sptlc2*), ceramide synthases (*Cers2-6*),
374 dihydroceramide desaturase-1 (*Degs1*) and sphingomyelin synthases (*Sgms1* and *Sgms2*), increased
375 with severity of NAFLD (**Suppl. Fig. 6**).

376 *Lipidomic analysis of liver tissue of NAFLD patients*

377 To further explore whether the changes in (dihydro)sphingolipid levels in mouse liver could
378 be replicated in human NAFLD, we analyzed the concentrations of lipid species in liver from 94
379 severe or morbidly obese patients subjected to bariatric surgery with NAFLD diagnosis established
380 via histology. The clinical, biochemical and demographic characteristics of the cohort are presented
381 in **Table 1** and the SAF scores in **Suppl. Fig. 7A**. Average age and BMI were determined as $48.1 \pm$
382 9.2 years and 46.4 ± 6.7 kg/m², with a female predominance (70%). Liver histology revealed some
383 degree of NAFLD in 73 participants (78%). The rates of hyperlipidemia, hypertension and T2DM
384 were higher in NAFLD than non-NAFLD groups, specifically in cases of NASH-fibrosis (**Table 1**).
385 The results of glycemetic parameters (Glu, HbA1c, homeostatic model assessment for insulin
386 resistance [HOMA-IR]) confirmed a worsening in the metabolic condition, particularly in the
387 NASH-fibrosis group. ALT displayed a slight increase under conditions of significant fibrosis,
388 whereas the plasma fibrosis biomarkers, such as hyaluronic acid (HA), cytokeratin-18 (CK18) and
389 tissue inhibitor metalloproteinase-1 (TIMP1), and fibrosis scores (ELF, FIB-4 and NFS) were
390 slightly increased with disease progression and aligned with severity of disease (**Table 1**).

391 Importantly, although non-NAFLD control livers were obtained from obese individuals
392 without histologically proven disease and not truly healthy subjects, the lipidomic analysis of liver
393 revealed a significant increase in neutral lipids (TG, CE and ACer) in NAFLD relative to non-
394 NAFLD groups (**Fig. 5A & Table 1**). Moreover, dhCer, dhSM and dhHexCer, and in particular,

395 lipid molecules containing very-long-chain fatty acids (**Fig. 5B**), showed a gradual increase from
396 NAFL to NASH-fibrosis conditions. These results in human liver were similar to that observed with
397 the mouse model. Levels of Cer and dhCer species correlated well with the values of TG species
398 (**Suppl. Fig. 8**). Likewise, we observed no differences in Cer and SM contents among NAFL,
399 NASH and NASH-fibrosis patient groups (**Table 1**). A significant correlation was evident in the
400 dihydrosphingolipid contents, especially dhCer, but not other sphingolipid classes (exemplified by
401 Cer) between liver and plasma (**Fig. 5C**).

402 *Plasma lipidomic analysis of NAFLD patients*

403 Previous liver biopsies were obtained from a cohort of obese patients with short
404 representation of stages F3–F4, which did not allow comprehensive evaluation of the behaviour of
405 lipid species in advanced fibrosis. Based on the correlation observed for dihydrosphingolipid
406 species between liver and plasma, we analyzed plasma samples including those from patients with
407 advanced fibrosis, with a view to defining the potential of plasma measurements as surrogate
408 biomarkers of histological lesions. The clinical, biochemical and histological characteristics of the
409 plasma cohort are presented in **Suppl. Fig. 7B** and **Table 2**. The average age (51.7 ± 11.2 years)
410 and BMI (41.3 ± 9.0 kg/m²) of the whole cohort was not markedly different from that of the
411 bariatric surgery cohort, but the proportion of females was slightly lower (59%, $p=0.043$), age of
412 NASH-fibrosis patients was higher, and BMI lower relative to the other groups. Rates of
413 hyperlipidemia, hypertension, T2DM and the trends in glycemic parameters were similar to those
414 described for the bariatric surgery cohort. Transaminase levels showed a slight increase with
415 progression from non-NAFLD to NASH-fibrosis. In the latter group, fibrogenesis test scores were
416 significantly higher compared to the remaining groups (**Table 2**).

417 Overall, lipidomic analysis of plasma samples of the full cohort revealed higher neutral lipid
418 and dihydrosphingolipid (dhCer, dhSM and dhHexCer) concentrations in NAFLD compared to
419 non-NAFLD patients (**Fig. 6A, B**). Similar to the findings in liver of both patients and model mice,

420 Cer and SM levels were not significantly affected by disease progression. However, we did not
421 detect an increase in plasma dihydrosphingolipid in patients with advanced fibrosis stages and
422 lower steatosis scores, similar to data obtained with mice, reflecting that plasma lipid changes
423 clearly do not represent a perfect surrogate of changes in liver.

424

425 **DISCUSSION**

426 NAFLD is a complex multifactorial disease with a histological spectrum spanning from
427 generally benign steatosis (NAFL) to steatosis with evidence of hepatocellular inflammation and
428 damage (NASH). The latter symptom appears in about 25% NAFLD patients, among which 5% go
429 on to develop NASH-fibrosis (26). The available evidence supports that overnutrition causing
430 central obesity and insulin resistance defines metabolic predisposition to NASH (27). Ceramides
431 and their immediate precursors, dihydroceramides, are implicated in NAFLD and other
432 comorbidities, such as obesity and T2DM (6). However, the relationship of (dihydro)sphingolipid
433 species with NAFLD progression remains to be established.

434 Here, we firstly explored the role of (dihydro)sphingolipids in a mouse model of NAFLD. To
435 date, no animal models have fully reproduced all the metabolic and histological hallmarks of human
436 NAFLD (28, 29). A minimum set of requirements in the animal model is demonstration of
437 metabolic aspects related to disease such as obesity, IR, and dyslipidemia, in addition to progressive
438 evolution of liver damage (26). Our regime of choice consisted of a high-fat and cholesterol diet
439 supplemented with high fructose and glucose. Glucose promotes hyperinsulinemia, which activates
440 liver FA synthesis by increasing mRNA expression and proteolytic cleavage of the nuclear
441 transcription factor SREBP1c (30), while fructose acts synergistically to promote *de novo*
442 lipogenesis and block β -fatty acid oxidation, leading to NAFLD development (31). Addition of high
443 cholesterol (1.25%) accelerates NASH development, directly activating myofibroblast
444 transformation of hepatic stellate cells (HSCs) (32). As a result, our model mice developed obesity
445 and IR at 22 weeks accompanied by progressive transaminase elevation and hypercholesterolemia.
446 However, hypertriglyceridemia was absent in our model, consistent with previous findings (33-35).
447 The reason for this phenomenon is not completely clear but may be attributed to the differences in
448 lipoprotein metabolism between humans and mice. The latter lacks cholesteryl ester transfer
449 protein, which may reduce the secretion of TG containing very-low density lipoproteins (VLDL) by
450 liver and stimulate high-density lipoprotein (HDL) production (36).

451 The model additionally demonstrated histological progression from NAFL to NASH, as
452 evident from the presence of a cluster of inflammatory cells and ballooned hepatocytes at 40 weeks.
453 The latter finding was confirmed by increased protein expression of p62, a proteasome component
454 and marker of Mallory-Denk bodies commonly found in human NASH (37). HSC activation and
455 myofibroblast transformation were validated by the increased protein and gene expression of α -
456 SMA and *Tfcb1*, respectively. Immunohistochemical analysis revealed association of the α -SMA
457 marker with formation of hCLS, linked with macrophage Kupffer cells surrounding cholesterol-
458 loaded hepatocytes and synthesis of collagen (38, 39).

459 One disadvantage of our murine model was that even after long-term feeding, disease in
460 animals did not progress to advanced fibrosis stages, consistent with earlier findings (40). For this
461 reason, we combined HFD feeding with CCl₄ as a fibrosis accelerator as reported in previous
462 studies (33). We observed progression to stages F3-F4 in 40% (3 out of 5) mice at 6 weeks and
463 100% animals after 10 weeks of CCl₄ treatment (33). However, CCl₄ administration was associated
464 with accelerated weight loss and amelioration of IR. Attenuation of IR could result from the blunted
465 weight gain, but was also observed in the HFD group of mice at 40 weeks, suggestive of effects of
466 fibrogenesis on IR. In summary, our mouse model could effectively replicate some of the key
467 metabolic, inflammatory and profibrotic pathways of human NAFLD.

468 Lipidomic analyses showed that changes in dihydrospingolipid species from liver and
469 plasma in the mouse model were more significant than those in sphingolipids. Relative to
470 sphingolipid species that are highly abundant in the diet, the dihydrospingolipid content is
471 extremely low (41). The majority of dihydrospingolipids were obtained directly from stimulation
472 of *de novo* synthesis in response to FFA overload, in keeping with earlier reports (8), and confirmed
473 by the increase in plasma and liver FFA concentrations in parallel with higher gene expression of
474 *Cd36*, a scavenger receptor that mediates the binding and cellular uptake of FFA (11) and stearyl-
475 CoA desaturase-1 (*Scd1*), a direct target of SREBP1c, which stimulates fatty acid desaturation and
476 TG synthesis (42). Moreover, the coordinated increase in gene expression of enzyme isoforms of

477 *Sptlc1-2, Cers2-6, Degs1* and *Sgms1-2* supports that liver of NAFLD mouse responds to the FFA
478 surplus, triggering not only synthesis of neutral lipids (TG, CE) but also early activation of the
479 ceramide synthesis pathway. In this context, increase in 1-o-acylceramide (ACer) catalyzed by the
480 same diacylglycerol acyltransferase 2 (DGAT2) responsible for TG synthesis (43), albeit at levels
481 four orders in magnitude lower in quantitative terms compared with TG, could be interpreted as a
482 result of the same spillover mechanism induced by excess liver FFAs.

483 Changes in neutral lipid classes (represented by TG, CE and ACer) were correlated with
484 histology and reflected in the steatosis score. However, advanced fibrosis stages (F3-F4) were
485 associated with lower steatosis scores and contents of neutral lipids. This phenomenon is similar to
486 the reduction of hepatic fat observed in patients with cryptogenic cirrhosis of NAFLD etiology
487 (burnt-out NASH) (44). However, advanced fibrosis dissociates the increase in dihydrosphingolipid
488 from the steatosis-linked neutral lipid increase observed in the mouse model (see **Suppl. Fig 5**). We
489 speculate that advanced fibrosis triggers the expression of sphingomyelinases (45), ceramidases
490 (46) and sphingosine kinases (47), reducing the available pool of Cer, in turn, promoting *de novo*
491 sphingolipid synthesis and increasing the dihydrosphingolipid concentration.

492 The concentrations of dihydrosphingolipids in mouse liver increased from NAFL to NASH-
493 fibrosis, especially those with VLCFA, such as dhCer 40:0, dhCer 42:0 and dhCer 42:1, whereas
494 Cer and SM-related species showed no changes or a decreasing trend with disease progression. The
495 general view is that liver respond to HFD feeding triggering the accumulation of C16-Cer and
496 decreasing the content of VLCFA-Cer (10, 48-50). However, more recently, loss of *Cers2* function,
497 which partially blocked the synthesis of VLCFA-Cer, failed to increase the Cer 34:1 concentration
498 in liver, even in mice fed a palmitic acid-enriched diet (51). The diet utilized in our study contained
499 a higher proportion of cholesterol and lower palmitic acid content than reported previously (10, 48,
500 49). Therefore, we hypothesize that the high-cholesterol content of our diet is responsible for
501 differences in the distribution of (dihydro)sphingolipid species relative to previous studies. The free
502 cholesterol (FC) content was almost double in liver of our NAFLD mice (**Suppl. Table S1**). A

503 major proportion of the excess content is esterified as CE, but the increase in FC is likely to affect
504 hepatocyte membrane composition where it is known to displace Cer, in particular, shorter C16-
505 Cer, and associate preferentially with VLCFA-Cer, SM and dihydrosphingolipid species (52).

506 Histological findings in the livers of bariatric surgery patients and plasma of the full NAFLD
507 cohort were similar to those in the mouse model upon classification according to SAF score (21).
508 Moreover, metabolic characteristics, dyslipidemia, IR and T2DM, evolution of fibrogenesis
509 biomarkers and even transaminase changes progressed in a comparable manner from non-NAFLD
510 to NASH-fibrosis. Lipidomic data from patient biopsies additionally showed many similarities in
511 the trends observed for neutral lipids (TG, CE and ACer) with the mouse model. Interestingly, we
512 observed equivalent changes in liver samples of NAFLD patients, with an increase in VLCFA-
513 dihydrosphingolipid species and no changes in Cer and SM groups, in keeping with recent
514 publications. On one hand, Vvedenskaya et al. (19) observed no major changes other than neutral
515 TG, DG and CE contents in liver between NAFL and NASH patient groups. Notably, the
516 concentrations of Cer and SM were similar between NAFL and NASH. On the other hand, Ooi and
517 co-workers (18) reported changes in dihydrosphingolipid species between non-NAFLD and
518 NAFLD but no differences between NAFL and NASH patient groups. Significant differences were
519 additionally observed for VLCFA-dhCer between the latter two groups.

520 Our data from model mice and patients support the theory that the increase in
521 dihydrosphingolipid is mediated by upregulation of *de novo* ceramide synthesis and linked to higher
522 steatosis scores. We observed a good correlation of dhCer levels between liver and plasma and TG
523 species in liver of patients but no significant associations for Cer species. Secretion of dhCer is
524 associated with TG and VLDL production, as recently shown by Carlier et al.(17). The same
525 authors reported that some dhCer species in plasma are associated with hepatic steatosis and NASH
526 in T2DM patients as well as increased liver gene expression of *Sptlc1*, *Degs1*, *Sgms1*, similar to
527 data obtained with our mouse model. Moreover, plasma dhCer was reported to be higher in
528 individuals who eventually progress to diabetes up to 9 years before disease onset (53), in

529 agreement with our interpretation of early stimulation of the *de novo* sphingolipid pathway in
530 comorbidities directly associated with NAFLD.

531 In view of the existence of good correlations between dihydrosphingolipid concentrations in
532 the liver and plasma, we were encouraged to extend the study to a larger cohort of patients with
533 advanced fibrosis stages to determine the potential of measurement of dihydrosphingolipids in
534 plasma as a biomarker of disease progression. Previous studies that attempted to address this
535 question recruited limited patients with significant fibrosis (F2-F4) (16, 18, 19, 54). Certain species
536 of TG (TG 50:1, TG 50:2, TG 52:2 and TG 54:2) in plasma appeared especially well suited to
537 differentiate between non-NAFL and NAFLD, even when fibrosis was observed, in agreement with
538 earlier findings. Plasma dihydrosphingolipids showed more significant associations with disease
539 progression than sphingolipids but their performance was not much better than that of TG species.
540 Overall, the benefit of measuring these lipid species over available low-cost laboratory assessments
541 of parameters, such as transaminases, and validated fibrosis scores, such as NAFLD fibrosis score
542 (NFS), Fibrosis-4 index (FIB-4) and Enhanced liver fibrosis score (ELF), appears to be of limited
543 utility in stratification of patients with NAFL, NASH and NASH-fibrosis.

544 One of the major strengths of our study is the detailed descriptions of liver and plasma lipid
545 profiles in the mouse model and NAFLD patient cohort, which showed similar histological and
546 metabolic alterations. The concentrations of (dihydro)sphingolipids and other lipid species were
547 analyzed following a validated methodology (24), which demonstrated excellent analytical stability.
548 The results were expressed as a molar concentration and shared in an open repository, which
549 facilitates future comparison with other lipidomic datasets from NAFLD patients and ongoing
550 efforts to harmonize methodology (55).

551 However, our study has several limitations that should be taken into consideration. Although
552 the transcriptomic and histological evolution of the mouse model is similar to human NAFLD (33),
553 mice in our experiments were subjected to an extreme diet regime and fibrosis accelerated with
554 CCl₄, a toxic agent which has no implications in human pathology (56). We could not differentiate

555 whether the metabolic findings in NASH-fibrosis mice were potentially driven by weight loss
556 induced by fibrosis evolution or whether progressive fibrosis was responsible for weight loss. In
557 fact, advanced fibrosis is associated with a hypermetabolic state (57), which may explain the
558 decrease in weight observed at the NASH-fibrosis stage in the mouse model and patients (see **Table**
559 **2**). We hypothesized that similar changes in (dihydro)sphingolipid species to those observed in the
560 liver of mice are likely to occur in patients with NASH-fibrosis. Unfortunately, we could only
561 analyze the concentrations of lipid species in liver samples of six patients with advanced fibrosis
562 from the bariatric surgery cohort. Hence, due to the inherent restrictions imposed by low
563 availability of samples obtained in liver percutaneous biopsies, we were only able to analyze plasma
564 samples from the cohort of patients with advanced fibrosis. Our results showed that although
565 significant, at best, changes in dihydrosphingolipid species observed in plasma of NAFLD patients
566 explained no more than ~50% of those in the liver ($R=0.52$, see **Fig. 5**). Therefore, we could not
567 fully extrapolate the trends in plasma to those in liver of patients. Moreover, we did not evaluate the
568 effects of the several genetic polymorphisms directly related to lipid metabolism, which are
569 implicated in changes observed in liver ceramides (15). Nevertheless, earlier studies indicate that
570 these risk genes do not seem to induce alterations in the liver lipidome (19). Another drawback, is
571 that non-NAFLD patient liver and plasma samples were obtained from obese individuals without
572 histologically proven disease and not truly healthy subjects and it might well be that
573 (dihydro)sphingolipid concentrations were higher in non-NAFLD obese than in healthy individuals.
574 Besides, the prospective single-point sampling nature of the study in both bariatric surgery and
575 plasma cohorts of patients did not allow us to draw conclusions about the stability of performed
576 measurements over time. Due to the inherent complexity of NAFLD, coordinated efforts including
577 studies on larger sets of NAFLD patients with histologically defined grading and staging of the
578 disease, elucidation of metabolic conditions and genetic risks, along with research focus on
579 harmonization of lipidomic analytical approaches are essential to define the roles of lipid species in
580 disease pathophysiology (58).

581 In conclusion, dihydrosphingolipid species accumulate in the liver of NAFLD patients,
582 coincident with the patterns observed in a mouse model. The increase in dihydrosphingolipids
583 reflects early stimulation of the *de novo* ceramide pathway in response to an increased burden of
584 free fatty acids in the liver. The concentrations of dihydrosphingolipids, particularly those with
585 very-long-chain fatty acids, correlates with liver triglycerides and steatosis grading based on
586 histology. Interestingly, the appearance of advanced fibrosis downregulates accumulation of neutral
587 lipids, but not dihydrosphingolipids in liver in the mouse model. While plasma
588 dihydrosphingolipids do not appear to achieve a higher diagnostic accuracy than the currently
589 available clinical chemistry tests, they provide valuable insights into the roles of lipid species in
590 NAFLD progression. Further studies combining standardized quantitative lipidomic and proteomic
591 approaches in well-defined cohorts of NAFLD patients are warranted to resolve the unmet need for
592 plasma surrogate biomarkers of histological lesions in these patient populations.
593

594 TABLES

595 **Table 1. Clinical and biochemical values in the bariatric surgery cohort.** Patients were
 596 classified according to their liver histological findings into four groups: non-NAFLD, simple
 597 steatosis (NAFL), steatohepatitis without significant fibrosis, stage of fibrosis F0-F1 (NASH) and
 598 steatohepatitis + stage of fibrosis F2-F4 (NASH-fibrosis). Values are expressed in % (N/N total in
 599 group) or mean \pm SD or (N total in group). (a) Significant, $p < 0.05$ from non-NAFLD. (b)
 600 Significant, $p < 0.05$ from NAFL. (c) Significant, $p < 0.05$ from NASH. (d) Significant, $p < 0.05$ from
 601 NASH-fibrosis.

Variable	non-NAFLD	NAFL	NASH	NASH-fibrosis
Demographics				
Number, %	22 (21/94)	47 (44/94)	16 (15/94)	15 (14/94)
Female, %	76 (16/21)	70 (31/44)	87 (13/15)	43 (6/14)
Hypertension, %	29 (6/21)	55 (24/44)	40 (6/15)	71 (10/14)
T2DM, %	29 (6/21)	52 (23/44)	47 (7/15)	71 (10/14)
Hyperlipidaemia, %	33 (7/21)	66 (29/44)	60 (9/15)	71 (10/14)
Anthropometry				
Age, y	43.1 \pm 2.2 (21) ^{b,c,d}	49.2 \pm 1.3 (44) ^a	49.0 \pm 2.3 (15) ^a	51.071 \pm 2.6 (14) ^a
Weight, Kg	121.7 \pm 4.5 (21) ^d	126.9 \pm 3.5 (44) ^d	119.3 \pm 6.5 (15) ^d	147.3 \pm 8.4 (14) ^{a,b,c}
BMI, Kg/m ²	44.5 \pm 1.3 (21) ^d	46.5 \pm 1.1 (44)	45.7 \pm 1.7 (15)	49.4 \pm 1.7 (14) ^a
Laboratory tests				
Glucose, mg/dL	91.3 \pm 4.0 (20) ^{b,c,d}	108.3 \pm 4.1 (43) ^{a,d}	113.7 \pm 8.5 (15) ^a	133.9 \pm 9.0 (14) ^{a,b}
HbA1c,	5.4 \pm 0.1 (19) ^{b,c,d}	6.2 \pm 0.2 (40) ^{a,d}	6.4 \pm 0.4 (15) ^a	7.3 \pm 0.4 (14) ^{a,b}
HOMA-IR	2.2 \pm 0.3 (20) ^{b,c,d}	4.3 \pm 0.4 (38) ^{a,d}	4.2 \pm 0.8 (11) ^{a,d}	7.2 \pm 1.2 (12) ^{a,b,c}
Insulin, μ U/mL	10.3 \pm 1.5 (21)	16.5 \pm 1.5 (38)	15.4 \pm 2.7 (11)	21.2 \pm 3.3 (12)
ALT, IU/mL	30.2 \pm 6.7 (20) ^d	27.5 \pm 2.3 (41)	32.1 \pm 4.1 (15)	44.9 \pm 7.6 (14) ^a
AST, IU/mL	24.7 \pm 6.0 (19) ^d	24.4 \pm 1.5 (43)	30.8 \pm 4.4 (15)	33.1 \pm 3.6 (14) ^a
GGT, IU/mL	21.2 \pm 4.4 (20) ^c	27.3 \pm 3.3 (41)	46.7 \pm 11.3 (15) ^a	42.6 \pm 11.7 (14)
Triglycerides, mg/dL	107.2 \pm 9.0 (19) ^{b,c,d}	165.7 \pm 13.0 (41) ^a	166.9 \pm 18.5 (15) ^a	186.9 \pm 36.1 (14) ^a
Cholesterol, mg/dL	164.4 \pm 8.0 (20)	171.4 \pm 6.2 (42)	168.1 \pm 10.5 (15)	181.8 \pm 10.9 (13)
HDLc, mg/dL	45.4 \pm 1.9 (20)	40.8 \pm 1.7 (40)	40.8 \pm 2.4 (15)	41.8 \pm 2.6 (14)
LDLc, mg/dL	102.3 \pm 6.8 (18)	99.2 \pm 5.7 (41)	93.6 \pm 9.7 (15)	103.6 \pm 8.4 (14)
Albumin, g/dL	3.9 \pm 0.1 (21)	4.0 \pm 0.1 (44)	4.0 \pm 0.1 (15)	3.9 \pm 0.1 (14)
Platelet, $\times 10^9$ /L	273.8 \pm 14.1 (21)	270.1 \pm 12.6 (43)	274.2 \pm 21.7 (14)	244.4 \pm 17.1 (14)
Fibrogenesis tests				
HA, ng/mL	25.8 \pm 5.5 (13) ^d	35.1 \pm 5.3 (24)	41.5 \pm 11.7 (6)	63.0 \pm 16.6 (14) ^a
PIIINP, ng/mL	4.9 \pm 0.4 (13) ^b	6.0 \pm 0.4 (24) ^a	8.8 \pm 3.3 (6)	6.2 \pm 0.7 (14)
TIMP, ng/mL	124.2 \pm 9.8 (13) ^d	137.4 \pm 5.5 (24) ^d	141.5 \pm 14.1 (6)	180.9 \pm 17.1 (14) ^{a,b}
CK18, U/L	135.5 \pm 21.8 (14) ^d	127.9 \pm 12.6 (24) ^d	124.3 \pm 17.4 (6) ^d	299.2 \pm 52.3 (14) ^{a,b,c}

ELF score	7.9 ± 0.3 (13) ^d	8.4 ± 0.1 (24)	8.7 ± 0.4 (6)	8.9 ± 0.2 (14) ^a
FIB-4 score	0.691 ± 0.077 (19) ^{b,d}	0.964 ± 0.076 (40) ^a	1.082 ± 0.205 (14)	1.12 ± 0.127 (14) ^a
NFS score	- 0.835 ± 0.317 (19) ^{b,d}	0.015 ± 0.258 (40) ^a	- 0.148 ± 0.453 (14)	0.703 ± 0.325 (14) ^a
<i>Liver lipid classes</i>				
TG, nmol/mg	30.1 ± 2.6 (21) ^{b,c,d}	68.3 ± 3.8 (44) ^{a,c,d}	80.5 ± 5.8 (15) ^{a,b}	96.4 ± 7.6 (14) ^{a,b}
CE, nmol/mg	14.3 ± 1.3 (21) ^{b,c,d}	23.8 ± 1.6 (44) ^{a,c,d}	35.7 ± 4.4 (15) ^{a,b}	29.9 ± 3.2 (14) ^{a,b}
FC, nmol/mg	54.7 ± 1.6 (21) ^{b,d}	59.5 ± 1.8 (44) ^{a,d}	54.6 ± 2.4(15) ^d	66.2 ± 1.9 (14) ^{a,b,c}
ACer, nmol/mg	0.006 ± 0.001 (21) ^{b,c,d}	0.019 ± 0.001 (44) ^{a,c,d}	0.032 ± 0.003 (15) ^{a,b,d}	0.047 ± 0.005 (14) ^{a,b,c}
Cer, nmol/mg	1.4 ± 0.1 (21)	1.6 ± 0.1 (44)	1.7 ± 0.2 (15)	1.7 ± 0.1 (14)
HexCer, nmol/mg	0.48 ± 0.03 (21) ^{b,c,d}	0.57 ± 0.02 (44) ^a	0.57 ± 0.04 (15) ^a	0.58 ± 0.04 (14) ^a
SM, nmol/mg	17.3 ± 0.6 (21)	17.3 ± 0.6 (44)	17.2 ± 0.8 (15)	17.6 ± 0.7 (14)
dhCer, nmol/mg	0.105 ± 0.011 (21) ^{c,d}	0.113 ± 0.007 (44) ^d	0.147 ± 0.019 (15) ^a	0.165 ± 0.021 (14) ^{a,b}
dhHexCer, nmol/mg	0.007 ± 0.001 (21) ^d	0.007 ± 0.001 (44) ^d	0.008 ± 0.001 (15)	0.010 ± 0.001 (14) ^{a,b}
dhSM, nmol/mg	3.46 ± 0.32 (21) ^d	3.26 ± 0.19 (44) ^d	3.56 ± 0.36 (15) ^d	4.88 ± 0.49 (14) ^{a,b,c}
LPC, nmol/mg	1.12 ± 0.09 (21)	1.12 ± 0.05 (44) ^d	1.11 ± 0.09 (15)	0.95 ± 0.06 (14) ^a
PC, nmol/mg	36.9 ± 2.7 (21) ^{c,d}	35.6 ± 1.9 (44) ^{c,d}	54.9 ± 4.4 (15) ^{a,b,d}	29.5 ± 1.8 (14) ^{a,b,c}
PE, nmol/mg	66.6 ± 4.3 (21) ^b	57.6 ± 2.4 (44) ^{a,d}	58.7 ± 3.9 (15)	66.0 ± 3.2 (14) ^b

602

603 T2DM. Type II diabetes mellitus ; HbA_{1c}, Glycated haemoglobin; HOMA-IR, homeostatic model
604 assessment for insulin resistance; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
605 GGT, Gamma glutamyltransferase; BMI, body mass index; HDLc, high-density lipoprotein
606 cholesterol; LDLc, Low-density lipoprotein cholesterol; HA, Hyaluronic Acid; PIIINP, Procollagen
607 III aminoterminal peptide; TIMP1, Tissue inhibitor of metalloproteinase-1; CK18, Apoptosis-
608 associated caspase-cleaved keratin-18. ELF, Enhanced liver fibrosis score; FIB-4, Fibrosis-4 index;
609 NFS, NAFLD fibrosis score.

610

611

612 **Table 2. Clinical and biochemical values in NAFLD patients from the plasma lipidomics**
 613 **cohort.** Patients were classified according to their liver histological findings into four groups: non-
 614 NAFLD, simple steatosis (NAFL), steatohepatitis without significant fibrosis, stage of fibrosis F0-
 615 F1 (NASH) and steatohepatitis + stage of fibrosis F2-F4 (NASH-fibrosis). Values are expressed in
 616 % (N/N total in group) or mean \pm SD or (N total in group). (a) Significant, $p < 0.05$ from non-
 617 NAFLD. (b) Significant, $p < 0.05$ from NAFL. (c) Significant, $p < 0.05$ from NASH. (d) Significant,
 618 $p < 0.05$ from NASH-fibrosis.

Variable	non-NAFLD	NAFL	NASH	NASH-fibrosis
Demographics				
Number, %	15 (29/195)	33 (65/195)	14 (27/195)	38 (74/195)
Female, %	69 (20/29)	65 (42/65)	63 (17/27)	49 (36/74)
Obesity, %	100 (29/29)	96 (26/65)	91 (59/27)	76 (56/74)
Hypertension, %	31 (9/29)	46 (30/65)	41 (11/27)	70 (52/74)
T2DM, %	21 (6/29)	38 (25/65)	44 (12/27)	78 (58/74)
Dyslipidaemia, %	31 (9/29)	71 (46/65)	67 (18/27)	81 (60/74)
Bariatric Surgery, %	100 (29/29)	78 (51/65)	63 (17/27)	19 (14/74)
Anthropometry				
Age, years	42.3 \pm 1.7 (29) ^{b,c,d}	49.3 \pm 1.1 (65) ^{a,d}	50.0 \pm 1.7 (27) ^{a,d}	58.0 \pm 1.3 (74) ^{a,b,c}
Weight, Kg	127.6 \pm 4.6 (29) ^{c,d}	119.3 \pm 3.0 (65) ^d	115.1 \pm 4.6 (27) ^a	107.2 \pm 3.8 (74) ^{a,b}
BMI, Kg/m ²	45.4 \pm 1.3 (29) ^{c,d}	43.4 \pm 1.1 (65) ^d	41.6 \pm 1.5 (27) ^{a,d}	37.7 \pm 1.1 (74) ^{a,b,c}
Laboratory tests				
Glucose, mg/dL	93.6 \pm 3.0 (28) ^{b,c,d}	109.4 \pm 4.9 (64) ^{a,d}	120.1 \pm 9.9 (27) ^{a,d}	142.4 \pm 6.2 (74) ^{a,b,c}
HbA1c,	5.4 \pm 0.1 (26) ^{c,d}	6.0 \pm 0.1 (61) ^d	6.4 \pm 0.3 (26) ^{a,d}	7.0 \pm 0.2 (67) ^{a,b,c}
HOMA-IR	2.7 \pm 0.4 (28) ^{b,c,d}	4.1 \pm 0.3 (58) ^{a,d}	5.4 \pm 0.7 (22) ^{a,d}	10.4 \pm 1.4 (43) ^{a,b,c}
Insulin, μ U/mL	12.0 \pm 1.6 (29) ^{c,d}	15.2 \pm 1.1 (58) ^d	18.0 \pm 1.9 (22) ^{a,d}	28.2 \pm 3.2 (43) ^{a,b}
ALT, IU/mL	28.1 \pm 4.8 (28) ^{c,d}	29.6 \pm 1.9 (62) ^{c,d}	38.6 \pm 3.8 (27) ^{a,b,d}	53.2 \pm 3.5 (74) ^{a,b,c}
AST, IU/mL	22.8 \pm 4.3 (27) ^d	24.4 \pm 1.4 (63) ^d	29.3 \pm 2.7 (27) ^d	43.0 \pm 2.4 (74) ^{a,b,c}
GGT, IU/mL	24.5 \pm 4.9 (28) ^{c,d}	32.1 \pm 3.7 (62) ^{c,d}	53.1 \pm 9.2 (27) ^{a,b,d}	104.4 \pm 11.2 (74) ^{a,b,c}
Triglycerides, mg/dL	107.3 \pm 7.5 (27) ^{b,c,d}	159.3 \pm 11.2 (62) ^a	157.9 \pm 13.2 (27) ^a	177.9 \pm 12.0 (74) ^a
Cholesterol, mg/dL	167.9 \pm 6.5 (28)	176.8 \pm 4.9 (63)	180.7 \pm 9.1 (27)	178.0 \pm 4.1 (73)
HDLc, mg/dL	45.0 \pm 1.6 (28) ^d	43.3 \pm 1.4 (61)	41.3 \pm 1.9(27)	41.3 \pm 1.0 (74) ^a
LDLc, mg/dL	105.0 \pm 5.8 (26)	106.2 \pm 4.7 (61)	110.9 \pm 7.9 (27)	106.7 \pm 3.5 (73)
Albumin, g/dL	3.9 \pm 0.1 (29)	3.9 \pm 0.1 (65)	4.0 \pm 0.1 (27)	3.9 \pm 0.1 (74)
Plaq. counts, $\times 10^9$ /L	280.1 \pm 11.1 (29) ^d	264.2 \pm 9.8 (64) ^d	263.5 \pm 14.5 (26) ^d	190.6 \pm 7.4 (74) ^{a,b,c}
Fibrogenesis tests				
HA, ng/mL	26.8 \pm 4.0 (20) ^{b,d}	38.0 \pm 4.3 (42) ^a	38.9 \pm 6.2 (17) ^{a,d}	135.6 \pm 27.0 (37) ^{a,b,c}

PIIINP, ng/mL	5.5 ± 0.4 (20) ^{b,c,d}	7.0 ± 0.4 (42) ^a	7.8 ± 1.2 (17) ^{a,d}	11.2 ± 0.9 (37) ^{a,b,c}
TIMP, ng/mL 1	122.9 ± 6.6 (20) ^{b,c,d}	168.4 ± 9.3 (42) ^a	192.4 ± 15.3(17) ^{a,d}	268.3 ± 17.2 (37) ^{a,b,c}
CK18, U/L	117.9 ± 16.1 (21) ^d	177.2 ± 29.8 (42) ^d	176.6 ± 35.5 (17) ^d	331.6 ± 32.0 (36) ^{a,b,c}
ELF score	8.0 ± 0.2 (20) ^{b,c,d}	8.6 ± 0.1 (42) ^{a,d}	8.7 ± 0.2 (17) ^{a,d}	10.0 ± 0.2 (37) ^{a,b,c}
FIB-4 score	0.649 ± 0.062 (27) ^{b,c,d}	0.939 ± 0.061 (60) ^a	0.979 ± 0.116 (26) ^{a,d}	2.156 ± 0.154 (74) ^{a,b,c}
NFS score	- 0.973 ± 0.236 (27) ^d	- 0.466 ± 0.209 (60) ^d	- 0.637 ± 0.306 (26) ^d	0.700 ± 0.144 (74) ^{a,b,c}
<i>Plasma lipid classes</i>				
TG, nmol/mL	233.0 ± 13.8 (29) ^{b,c,d}	297.7 ± 10.3 (65) ^a	307.4 ± 20.5 (27) ^a	318.1 ± 13.2 (74) ^a
CE, nmol/mL	3574 ± 272 (29) ^b	4254 ± 191 (65) ^{a,d}	4097 ± 303 (27)	3634 ± 143 (74) ^b
FC, nmol/mL	1370 ± 50 (29) ^b	1554 ± 44 (65) ^a	1513 ± 78 (27)	1460 ± 35 (74)
ACer, nmol/mL	0.153 ± 0.009 (29) ^{b,c,d}	0.194 ± 0.007 (65) ^a	0.192 ± 0.013 (27) ^{a,d}	0.229 ± 0.01 (74) ^{a,b,c}
Cer, nmol/mL	5.5 ± 0.3 (29) ^{b,d}	6.5 ± 0.2 (65) ^a	6.3 ± 0.4 (27)	6.3 ± 0.2 (74) ^a
HexCer, nmol/mL	6.8 ± 0.4 (29)	7.0 ± 0.3 (65)	7.3 ± 0.5 (27)	7.5 ± 0.3 (74)
SM, nmol/mL	355.3 ± 13.2 (29)	372.6 ± 8.7 (65) ^d	388.4 ± 21.5 (27)	349.4 ± 7.7 (74) ^b
dhCer, nmol/mL	0.66 ± 0.05 (29) ^d	0.76 ± 0.03 (65) ^d	0.76 ± 0.06 (27)	0.87 ± 0.04 (74) ^{a,b}
dhHexCer, nmol/mL	0.044 ± 0.002 (29) ^d	0.049 ± 0.002 (65) ^d	0.051 ± 0.004 (27) ^d	0.061 ± 0.003 (74) ^{a,b,c}
dhSM, nmol/mL	33.7 ± 1.5 (29)	32.9 ± 1.2 (65)	33.1 ± 1.8 (27)	33.8 ± 1.3 (74)
LPC, nmol/mL	131.1 ± 8.0 (29) ^{b,d}	153.3 ± 6.8 (65) ^a	154.2 ± 9.2 (27)	175.4 ± 6.8 (74) ^{a,b}
PC, nmol/mL	1071 ± 45 (29) ^{b,d}	1192 ± 39 (65) ^a	1193 ± 59 (27)	1249 ± 44 (74) ^a
PE, nmol/mL	41.5 ± 3.4 (29) ^{b,c,d}	51.4 ± 2.3 (65) ^a	57.0 ± 4.6 (27) ^a	57.0 ± 3.1 (74) ^a

619

620 T2DM. Type II diabetes mellitus ; HbA1c, Glycated haemoglobin; HOMA-IR, homeostatic model
621 assessment for insulin resistance; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
622 GGT, Gamma glutamyltransferase; BMI, body mass index; HDLc, high-density lipoprotein
623 cholesterol; LDLc, Low-density lipoprotein cholesterol; HA, Hyaluronic Acid; PIIINP, Procollagen
624 III aminoterminal peptide; TIMP1, Tissue inhibitor of metalloproteinase 1; CK18, Apoptosis-
625 associated caspase-cleaved keratin 18. ELF, Enhanced liver fibrosis score; FIB-4, Fibrosis-4 index;
626 NFS, NAFLD fibrosis score.

627

628

629 **FIGURE LEGENDS**

630 **Fig. 1. Metabolic characterization of the NAFLD mice model.** (A) 8 weeks year old mice were
631 treated with HFD (+ fructose and glucose in water) up to 40 weeks. At 22 weeks a subgroup of
632 mice was treated with CCl₄ for 6 and 10 weeks. Body weight change during the follow-up period.
633 Normal chow diet for 22 weeks and 30 weeks (CNT, n=14); HFD for 22 weeks (HFD 22w, n=19);
634 HFD for 30 weeks (HFD 30w, n=6); HFD for 40 weeks (HFD 40w, n =5), HFD 22w+CCl₄ for 6
635 weeks (CCl₄ 6w, n=5), HFD 22w+CCl₄ for 10 weeks (CCl₄ 10w, n=14). (B) Liver weight (LW).
636 (C) liver per body weight ratio (LW/BW). (D) Plasma ALT. (E) Plasma AST. (F) Plasma total
637 cholesterol. (G) Plasma total triglycerides. (H) Plasma high-density lipoprotein cholesterol. (I)
638 Fasting blood glucose. (J) Oral glucose tolerance test. (H) Area under the curve in the OGTT.
639 Results were expressed as mean ± SD. For better clarity, only the student t-test comparison respect
640 to the CNT group for HFD 22w, HFD 30w, and HFD 40w and CCl₄ 6w, CCl₄ 10w respect to HFD
641 22w, are showed. *p <0.05, **p <0.01, ***p <0.001, **** p<0.0001. ALT, alanine
642 aminotransferase; AST, aspartate aminotransferase; CCl₄, carbon tetrachloride; HFD, high fat diet;
643 CNT, normal chow diet; Chol, total cholesterol; Trig, total triglycerides; Glu, glucose; HDLc, high-
644 density lipoprotein cholesterol; OGTT, oral glucose tolerance test; AUC, area under the curve, LW,
645 Liver weight, BW, body weight.

646

647 **Fig. 2. Histological features correlate with protein and gene expression biomarkers or disease**
648 **progression in the mice model.** (A) Macroscopic appearance, hematoxylin and eosin, and sirius
649 red staining of representative liver from mice on normal chow diet for 22 weeks (CNT 22w); high-
650 fat diet HFD for 22 weeks (HFD 22w); HFD for 30 weeks (HFD 30w); HFD for 40 weeks (HFD
651 40w), HFD 22w+CCl₄ for 6 weeks (CCl₄ 6w) and HFD 22w+CCl₄ for 10 weeks (CCl₄ 10w).
652 Original magnification x100. (B) Representative Western-blot of PLIN2, α-SMA, p62, COLA1A
653 and housekeeping standard HSP90 in liver lysates from CNT 22w, HFD 22w, HFD 30w, HFD 40w,

654 CCl₄ 10w. (C) Densitometric analysis of the ratio of PLIN2, α -SMA, p62 and COLA1A,
655 normalized by HSP90. Data represent the mean \pm SD of n=5 samples per condition. (C) Gene
656 expression levels of *Cd36*, *Scd1*, *Tnfa* and *Tfgeb1* in the liver of CNT 22w, HFD 22w, HFD 30w,
657 HFD 40w, CCl₄ 10w. Data represent the mean \pm SD of n=5 samples per condition. *p <0.05, **p
658 <0.01, ***p <0.001. ****p <0.0001.

659

660 **Fig. 3. Dihydrospingolipid evolution is associated to the increase in FFA in the mice model.**

661 (A) Time-course of plasma sphingolipid classes: Cer, dhCer, SM, dhSM in normal chow (CNT) and
662 high-fat diet (+fructose and glucose). Lipid classes were calculated as the sum composition from
663 the corresponding lipid species. Data represent the mean \pm SEM of n=3-4 animals per group. (B)
664 AUC of sphingolipid molecular species. Data represent the mean \pm SEM of n=3-4 animals per
665 group. (C) FFA in plasma and liver tissue samples from mice on normal chow diet for 22 weeks
666 (CNT 22w); high-fat diet HFD for 22 weeks (HFD 22w); HFD for 30 weeks (HFD 30w); HFD for
667 40 weeks (HFD 40w), HFD 22w+CCl₄ for 6 weeks (CCl₄ 6w). Data represent the mean \pm SD of
668 n=5-7 animals per group. ** p<0.01. Cer, ceramide; dhCer, dihydroceramide; SM, sphingomyelin;
669 dhSM, dihydrospingomyelin. FFA, free fatty acids.

670

671 **Fig. 4. Lipidomic analysis of (dihydro)spingolipids in NAFLD mice liver.** (A) Quantitative
672 analysis of lipid species from 10 classes (see Suppl. Table 2 for class concentrations), were
673 determined in livers of mice histologically classified as: non-NAFLD (n=7), simple steatosis
674 (NAFL, n=17), steatohepatitis without significant fibrosis, stage of fibrosis F0-F1 (NASH, n=9) and
675 steatohepatitis + stage of fibrosis F2-F4 (NASH-fibrosis, n=24). The values of Log₂-fold change of
676 each animal (column) and each lipid specie (row) is plotted in the in the heatmap and ordered by the
677 hierarchical clustering of individuals (columns). (B) Hepatic concentrations of representative
678 species of TG, dhSM, dhCer, dhHexCer, Cer and SM. Average values are represented as boxplots,
679 with points showing the value of each mice. *p <0.05, *p <0.01, ***p <0.001 and ****p <0.001,

680 using Student's t-test. TG, triglyceride; CE, Cholesteryl ester; FC, free cholesterol; ACer, 1-o-
681 Acylceramide; Cer, ceramide; HexCer, hexosylceramide; SM, Sphingomyelin; dhCer,
682 dihydroceramide; dhHexCer, dihydrohexosylceramide dhSM, dihydrosphingomyelin. NASF;
683 NASH-fibrosis

684

685 **Fig. 5. Lipidomic analysis of (dihydro)sphingolipids of livers from the bariatric surgery**

686 **cohort.** (A) Quantitative analysis of lipid species from 10 classes (see Table 1 for lipid class

687 concentrations), were determined in livers of patients histologically classified as: non-NAFLD

688 (n=21), simple steatosis (NAFL, n=44), steatohepatitis without significant fibrosis, stage of fibrosis

689 F0-F1 (NASH, n=15) and steatohepatitis + stage of fibrosis F2-F4 (NASH-fibrosis, n=14). The

690 values of Log₂-fold change of each patient (column) and each lipid specie (row) is plotted in the in

691 the heatmap and ordered by the hierarchical clustering of individuals (columns). (B) Hepatic

692 concentrations of representative species of TG, dhSM, dhCer, dhHexCer, Cer and SM. Average

693 values are represented as boxplots, with points showing the value of each patient. (C) Correlation

694 plot between plasma and liver concentrations for Cer, dhCer and TG. *p <0.05, **p <0.01, ***p

695 <0.001 and ****p <0.001, using Student's t-test or the Pearson's correlation coefficient. TG,

696 triglyceride; CE, Cholesteryl ester; FC, free cholesterol; ACer, 1-o-Acylceramide; Cer, ceramide;

697 HexCer, hexosylceramide; SM, Sphingomyelin; dhCer, dihydroceramide; dhHexCer,

698 dihydrohexosylceramide dhSM, dihydrosphingomyelin. NASF; NASH-fibrosis

699

700 **Fig. 6. Lipidomic analysis of (dihydro)sphingolipids in plasma of NAFLD patients.** (A)

701 Quantitative analysis of lipid species from 10 classes (see Table 2 for lipid class concentrations),

702 were determined in livers of patients histologically classified as: non-NAFLD (n=29), simple

703 steatosis (NAFL, n=65), steatohepatitis without significant fibrosis, stage of fibrosis F0-F1 (NASH,

704 n=27) and steatohepatitis + stage of fibrosis F2-F4 (NASH-fibrosis, n=74). The values of Log₂-fold

705 change of each patient (column) and each lipid specie (row) is plotted in the in the heatmap and

706 ordered by the hierarchical clustering of individuals (columns). (B) Hepatic concentrations of

707 representative species of TG, dhSM, dhCer, dhHexCer, Cer and SM. Average values are
708 represented as boxplots, with points showing the value of each patient. *p <0.05, **p <0.01, ***p
709 <0.001 and ****p <0.001, using Student's t-test. TG, triglyceride; CE, Cholesteryl ester; FC, free
710 cholesterol; ACer, 1-o-Acylceramide; Cer, ceramide; HexCer, hexosylceramide; SM,
711 Sphingomyelin; dhCer, dihydroceramide; dhHexCer, dihydrohexosylceramide dhSM,
712 dihydrosphingomyelin. NASF; NASH-fibrosis
713

714 **ACKNOWLEDGMENTS**

715 We thank the Quantification and Molecular Characterization Unit (UCA-CCM IRYCIS) for
716 their technical help. JL Rodríguez-Navarro for helping with animals. P. Mediavilla, D. Mora, L.
717 Alcázar and I. Candela for their assistance with blood biochemistry assays and International
718 Science Editing for English style revision.

719

720

721

722

723 **REFERENCES**

724

- 725 1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new
726 definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus
727 statement. *Journal of hepatology*. 2020;73(1):202-9.
- 728 2. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and
729 management of nonalcoholic fatty liver disease: Practice guidance from the American Association
730 for the Study of Liver Diseases. *Hepatology (Baltimore, Md)*. 2018;67(1):328-57.
- 731 3. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwittaya P,
732 et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of
733 Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2015;149(2):389-97 e10.
- 734 4. Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al.
735 Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. *The New England*
736 *journal of medicine*. 2021;385(17):1559-69.
- 737 5. Samuel VT, Shulman GI. Nonalcoholic Fatty Liver Disease, Insulin Resistance, and
738 Ceramides. *The New England journal of medicine*. 2019;381(19):1866-9.
- 739 6. Hajduch E, Lachkar F, Ferre P, Foufelle F. Roles of Ceramides in Non-Alcoholic Fatty Liver
740 Disease. *J Clin Med*. 2021;10(4).
- 741 7. Green CD, Maceyka M, Cowart LA, Spiegel S. Sphingolipids in metabolic disease: The good,
742 the bad, and the unknown. *Cell metabolism*. 2021;33(7):1293-306.
- 743 8. Summers SA, Chaurasia B, Holland WL. Metabolic Messengers: ceramides. *Nat Metab*.
744 2019;1(11):1051-8.
- 745 9. Jiang M, Li C, Liu Q, Wang A, Lei M. Inhibiting Ceramide Synthesis Attenuates Hepatic
746 Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease. *Front Endocrinol (Lausanne)*.
747 2019;10:665.
- 748 10. Kim YR, Lee EJ, Shin KO, Kim MH, Pewzner-Jung Y, Lee YM, et al. Hepatic triglyceride
749 accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide
750 synthases. *Exp Mol Med*. 2019;51(11):1-16.
- 751 11. Chaurasia B, Tippetts TS, Mayoral Monibas R, Liu J, Li Y, Wang L, et al. Targeting a
752 ceramide double bond improves insulin resistance and hepatic steatosis. *Science*.
753 2019;365(6451):386-92.
- 754 12. Raichur S, Wang ST, Chan PW, Li Y, Ching J, Chaurasia B, et al. CerS2 haploinsufficiency
755 inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin
756 resistance. *Cell metabolism*. 2014;20(4):687-95.

- 757 13. Ichi I, Nakahara K, Fujii K, Iida C, Miyashita Y, Kojo S. Increase of ceramide in the liver and
758 plasma after carbon tetrachloride intoxication in the rat. *Journal of nutritional science and*
759 *vitaminology*. 2007;53(1):53-6.
- 760 14. Apostolopoulou M, Gordillo R, Koliaki C, Gancheva S, Jelenik T, De Filippo E, et al. Specific
761 Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in
762 Nonalcoholic Steatohepatitis. *Diabetes Care*. 2018;41(6):1235-43.
- 763 15. Luukkonen PK, Zhou Y, Sadevirta S, Leivonen M, Arola J, Oresic M, et al. Hepatic ceramides
764 dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. *Journal of*
765 *hepatology*. 2016;64(5):1167-75.
- 766 16. Jung Y, Lee MK, Puri P, Koo BK, Joo SK, Jang SY, et al. Circulating lipidomic alterations
767 in obese and non-obese subjects with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*.
768 2020;52(10):1603-14.
- 769 17. Carlier A, Phan F, Szpigel A, Hajduch E, Salem JE, Gautheron J, et al. Dihydroceramides in
770 Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in
771 Type 2 Diabetes. *Cell Rep Med*. 2020;1(9):100154.
- 772 18. Ooi GJ, Meikle PJ, Huynh K, Earnest A, Roberts SK, Kemp W, et al. Hepatic lipidomic
773 remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic
774 steatohepatitis. *Journal of hepatology*. 2021.
- 775 19. Vvedenskaya O, Rose TD, Knittelfelder O, Palladini A, Wodke JAH, Schumann K, et al.
776 Non-alcoholic fatty liver disease Stratification by Liver Lipidomics. *Journal of lipid research*.
777 2021:100104.
- 778 20. Satapathy SK, Kuwajima V, Nadelson J, Atiq O, Sanyal AJ. Drug-induced fatty liver disease:
779 An overview of pathogenesis and management. *Annals of hepatology*. 2015;14(6):789-806.
- 780 21. Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological
781 algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. *Hepatology*
782 (Baltimore, Md). 2012;56(5):1751-9.
- 783 22. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR.
784 *Nucleic Acids Res*. 2001;29(9):e45.
- 785 23. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance
786 test in mice. *American journal of physiology Endocrinology and metabolism*. 2008;295(6):E1323-
787 32.
- 788 24. Babiy B, Busto R, Pastor O. A normalized signal calibration with a long-term reference
789 improves the robustness of RPLC-MRM/MS lipidomics in plasma. *Analytical and bioanalytical*
790 *chemistry*. 2021;413(15):4077-90.

- 791 25. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of
792 total lipides from animal tissues. *The Journal of biological chemistry*. 1957;226(1):497-509.
- 793 26. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology
794 of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
795 *Hepatology (Baltimore, Md)*. 2016;64(1):73-84.
- 796 27. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of
797 nonalcoholic fatty liver disease. *Cell*. 2021;184(10):2537-64.
- 798 28. Farrell G, Schattenberg JM, Leclercq I, Yeh MM, Goldin R, Teoh N, et al. Mouse Models of
799 Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic
800 Steatohepatitis. *Hepatology (Baltimore, Md)*. 2019;69(5):2241-57.
- 801 29. Jahn D, Kircher S, Hermanns HM, Geier A. Animal models of NAFLD from a hepatologist's
802 point of view. *Biochim Biophys Acta Mol Basis Dis*. 2018.
- 803 30. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. *Cell*
804 *metabolism*. 2008;7(2):95-6.
- 805 31. Jensen T, Abdelmalek MF, Sullivan S, Nadeau KJ, Green M, Roncal C, et al. Fructose and
806 sugar: A major mediator of non-alcoholic fatty liver disease. *Journal of hepatology*. 2018;68(5):1063-
807 75.
- 808 32. Tomita K, Teratani T, Suzuki T, Shimizu M, Sato H, Narimatsu K, et al. Free cholesterol
809 accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic
810 steatohepatitis in mice. *Hepatology (Baltimore, Md)*. 2014;59(1):154-69.
- 811 33. Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, et al. A simple diet- and
812 chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver
813 cancer. *Journal of hepatology*. 2018;69(2):385-95.
- 814 34. Gallou-Kabani C, Vige A, Gross MS, Rabes JP, Boileau C, Larue-Achagiotis C, et al.
815 C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome. *Obesity*
816 *(Silver Spring)*. 2007;15(8):1996-2005.
- 817 35. Wong SK, Chin KY, Suhaimi FH, Fairus A, Ima-Nirwana S. Animal models of metabolic
818 syndrome: a review. *Nutrition & metabolism*. 2016;13:65.
- 819 36. Podrini C, Cambridge EL, Lelliott CJ, Carragher DM, Estabel J, Gerdin AK, et al. High-fat
820 feeding rapidly induces obesity and lipid derangements in C57BL/6N mice. *Mamm Genome*.
821 2013;24(5-6):240-51.
- 822 37. Zatloukal K, French SW, Stumptner C, Strnad P, Harada M, Toivola DM, et al. From Mallory
823 to Mallory-Denk bodies: what, how and why? *Exp Cell Res*. 2007;313(10):2033-49.

- 824 38. Itoh M, Kato H, Suganami T, Konuma K, Marumoto Y, Terai S, et al. Hepatic crown-like
825 structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans. *PloS one*.
826 2013;8(12):e82163.
- 827 39. Ioannou GN, Subramanian S, Chait A, Haigh WG, Yeh MM, Farrell GC, et al. Cholesterol
828 crystallization within hepatocyte lipid droplets and its role in murine NASH. *Journal of lipid research*.
829 2017;58(6):1067-79.
- 830 40. Krishnan A, Abdullah TS, Mounajjed T, Hartono S, McConico A, White T, et al. A
831 longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing
832 NASH with high fidelity to the human condition. *American journal of physiology Gastrointestinal
833 and liver physiology*. 2017;312(6):G666-G80.
- 834 41. Wan J, Li J, Bandyopadhyay S, Kelly SL, Xiang Y, Zhang J, et al. Analysis of 1-
835 Deoxysphingoid Bases and Their N-Acyl Metabolites and Exploration of Their Occurrence in Some
836 Food Materials. *Journal of agricultural and food chemistry*. 2019;67(46):12953-61.
- 837 42. Sampath H, Miyazaki M, Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase-1 mediates the
838 pro-lipogenic effects of dietary saturated fat. *The Journal of biological chemistry*. 2007;282(4):2483-
839 93.
- 840 43. Senkal CE, Salama MF, Snider AJ, Allopenna JJ, Rana NA, Koller A, et al. Ceramide Is
841 Metabolized to Acylceramide and Stored in Lipid Droplets. *Cell metabolism*. 2017;25(3):686-97.
- 842 44. van der Poorten D, Samer CF, Ramezani-Moghadam M, Coulter S, Kacevska M, Schrijnders
843 D, et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin
844 the cause? *Hepatology (Baltimore, Md)*. 2013;57(6):2180-8.
- 845 45. van Koppen A, Verschuren L, van den Hoek AM, Verheij J, Morrison MC, Li K, et al.
846 Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a
847 Translational NASH Mouse Model. *Cell Mol Gastroenterol Hepatol*. 2018;5(1):83-98 e10.
- 848 46. Alsamman S, Christenson SA, Yu A, Ayad NME, Mooring MS, Segal JM, et al. Targeting
849 acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice. *Science translational
850 medicine*. 2020;12(557).
- 851 47. Mauer AS, Hirsova P, Maiers JL, Shah VH, Malhi H. Inhibition of sphingosine 1-phosphate
852 signaling ameliorates murine nonalcoholic steatohepatitis. *American journal of physiology
853 Gastrointestinal and liver physiology*. 2017;312(3):G300-G13.
- 854 48. Kasumov T, Li L, Li M, Gulshan K, Kirwan JP, Liu X, et al. Ceramide as a mediator of non-
855 alcoholic Fatty liver disease and associated atherosclerosis. *PloS one*. 2015;10(5):e0126910.
- 856 49. Raichur S, Brunner B, Bielohuby M, Hansen G, Pfenninger A, Wang B, et al. The role of
857 C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel
858 therapeutic approach. *Molecular metabolism*. 2019;21:36-50.

- 859 50. Hammerschmidt P, Ostkotte D, Nolte H, Gerl MJ, Jais A, Brunner HL, et al. CerS6-Derived
860 Sphingolipids Interact with Mff and Promote Mitochondrial Fragmentation in Obesity. *Cell*.
861 2019;177(6):1536-52 e23.
- 862 51. Nicholson RJ, Poss AM, Maschek JA, Cox JE, Hopkins PN, Hunt SC, et al. Characterizing a
863 Common CERS2 Polymorphism in a Mouse Model of Metabolic Disease and in Subjects from the
864 Utah CAD Study. *J Clin Endocrinol Metab*. 2021;106(8):e3098-e109.
- 865 52. Alonso A, Goni FM. The Physical Properties of Ceramides in Membranes. *Annu Rev*
866 *Biophys*. 2018;47:633-54.
- 867 53. Wigger L, Cruciani-Guglielmacci C, Nicolas A, Denom J, Fernandez N, Fumeron F, et al.
868 Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans.
869 *Cell reports*. 2017;18(9):2269-79.
- 870 54. Mayo R, Crespo J, Martinez-Arranz I, Banales JM, Arias M, Minchole I, et al. Metabolomic-
871 based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and
872 validation cohorts. *Hepatology communications*. 2018;2(7):807-20.
- 873 55. Liebisch G, Ekroos K, Hermansson M, Ejsing CS. Reporting of lipidomics data should be
874 standardized. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2017;1862(8):747-51.
- 875 56. Castro RE, Diehl AM. Towards a definite mouse model of NAFLD. *Journal of hepatology*.
876 2018;69(2):272-4.
- 877 57. Anand AC. Nutrition and Muscle in Cirrhosis. *J Clin Exp Hepatol*. 2017;7(4):340-57.
- 878 58. Masoodi M, Gastaldelli A, Hyotylainen T, Arretxe E, Alonso C, Gaggini M, et al.
879 Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. *Nat Rev*
880 *Gastroenterol Hepatol*. 2021;18(12):835-56.
- 881


Fig. 1





Fig. 2**A****B****C****D**

Fig. 3




Fig. 4









Fig. 5**A****B****C**

Fig. 6


Supplementary Figures

Suppl. Fig. 1




Suppl. Fig. 2

Chow diet (CNT)




High Fat Diet (HFD)



● Plasma sampling

▼ Plasma & tissue sampling


Suppl. Fig. 3




Suppl. Fig. 4

A


group/score	Steatosis				Activity					Fibrosis				
	S0	S1	S2	S3	A0	A1	A2	A3	A4	F0	F1	F2	F3	F4
CNT 22w	7	NA	NA	NA	7	NA	NA	NA	NA	7	NA	NA	NA	NA
HFD 22w	NA	5	8	6	4	11	1	3	NA	16	3	NA	NA	NA
HFD 30w	NA	NA	NA	7	NA	1	NA	4	2	2	5	NA	NA	NA
HFD 40w	NA	NA	NA	5	NA	NA	NA	NA	5	NA	NA	5	NA	NA
CCl ₄ 6w	NA	1	2	2	NA	2	3	NA	NA	NA	NA	3	1	1
CCl ₄ 10w	4	9	1	NA	1	4	9	NA	NA	NA	NA	NA	13	1



B




Suppl. Fig. 5





Suppl. Fig. 6

□ non-NAFLD ■ NAFL ■ NASH ■ NASHF




Liver cohort

Plasma cohort




Suppl.Fig. 8

A



B



Suppl. Fig. 9

